Is Arrowhead Pharmaceuticals Inc (ARWR) a risky stock?
As of July 25, 2026, Clavix grades Arrowhead Pharmaceuticals Inc (ARWR) C- for risk, a composite score of 63 out of 100 on an A+ to F scale, which puts ARWR in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 25, 2026. Clavix regrades every trading day.
ARWR price, last 3 months
ARWR's daily closes over the past three months. Clavix reads risk from the fundamentals and news behind the price, not the line itself.
The five risk dimensions behind ARWR's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ARWR scores on each, as of July 25, 2026.
What's moving ARWR's risk right now
Company-specific signals Clavix flags behind ARWR's current grade, drawn from recent news and filings as of July 25, 2026.
Strong Phase 3 efficacy and safety data position plozasiran for an expanded label, potentially broadening its commercial market beyond its current rare disease approval and drivin…
Raised guidance reduces near-term uncertainty and is often a leading indicator of further upward estimate revisions.
Earnings are roughly in line with expectations, providing little catalyst in either direction.
Recent ARWR news
The latest headlines Clavix ingested for Arrowhead Pharmaceuticals Inc, newest first. These feed the news-sentiment dimension of ARWR's grade.
-
Bank of New York Mellon Corp increased its stake in Arrowhead Pharmaceuticals (ARWR) by 72,296 shares (8.1%) during Q1, bringing total holdings to 960,144 shares. The article text is truncated, limiting further details.
-
Analysts’ Price Target Changes for July 23rd (ARWR, BEPC, BMI, CCI, CME, CROX, CSX, FOOD, GEV, GOOG)
Morgan Stanley raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) from $100.00 to $120.00, maintaining an overweight rating.
-
Morgan Stanley Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock
Morgan Stanley raised its price target on Arrowhead Pharmaceuticals (ARWR) from $100 to $120 and maintained an Overweight rating in a research report on Thursday.
What a C- grade means
On the Clavix A+ to F scale, ARWR's composite of 63 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ARWR or any security. Grades are risk indicators, not predictions of return. Data may be delayed.